Amgen Inc., the Thousand Oaks-based biotech firm, tapped Latham & Watkins for a $4.5 billion offering of investment-grade notes. Shearman & Sterling represented the syndicate of 18 underwriters, led by Morgan Stanley.
The drugmaker will use the proceeds to repurchase shares of a subsidiary, ATL Holdings Limited, as well as repay certain borrowings under its term loan. Amgen undertook those financings to pay for its October 2013 acquisition of San Francisco-based Onyx Pharmaceuticals, a $9.7 billion transaction.
